Last reviewed · How we verify
NCT07158801
Project EMPOWER-OCD
Phase 1 trial testing Project EMPOWER-OCD in Obsessive-Compulsive Disorder in 110 participants. Not yet recruiting.
31 August 2026
Quick facts
| Lead sponsor | Boston University Charles River Campus |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 1 October 2025 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Project EMPOWER-OCD
- Project CARE
Conditions studied
- Obsessive-Compulsive Disorder — all drugs for Obsessive-Compulsive Disorder →
Sponsor
Boston University Charles River Campus
Who can join
18 and older, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study aims to adapt and evaluate the acceptability and effectiveness of Project EMPOWER-OCD for socioeconomically diverse caregivers of patients with OCD. Designed to reduce obstacles (e.g. months long time commitment, high cost, transportation) to treatment that caregivers may be particularly prone to, project EMPOWER-OCD will provide targeted intervention of accommodation - a well-established, potentially modifiable risk factor for child anxiety, OCD, and its related disorders - in a single, self-guided session via an online format.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07158801
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obsessive-Compulsive Disorder
Currently open trials in the same condition.
- NCT06575075 — Pilot Study of RR-HNK in OCD · Phase 1, PHASE2 · recruiting
- NCT05783817 — MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) · Phase 2 · recruiting
- NCT07065669 — Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation · NA · recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
- NCT07000812 — EEG Evaluation of CBT for Obsessive-Compulsive Disorder · NA · active not recruiting
Other Boston University Charles River Campus trials
Trials by the same sponsor.
- NCT07461584 — Memory Enhancement in Aging With Optimal Dosing · EARLY_PHASE1 · not yet recruiting
- NCT07208318 — Restructuring the Alpha-Gamma Code in Aging Vision · EARLY_PHASE1 · not yet recruiting
- NCT06182241 — Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South · NA · not yet recruiting
- NCT05624931 — Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa · NA · recruiting
- NCT06940843 — A Pilot Randomized Controlled Trial of the Hopeful and Healthy Living Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07158801 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston University Charles River Campus
- Last refreshed: 11 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07158801.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing